Oral antifungal drug interactions: A mechanistic approach to understanding their cause

Dermatologic Clinics

Volumn 21, Issue 3, 2003, Pages 543-563

  Katz, H Irving ^a,d   Gupta, Aditya K ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c MEDIPROBE RESEARCH INC   (Canada)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLOROQUINE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DIGOXIN; ETOPOSIDE; FLUCONAZOLE; GLYCOPROTEIN P; GRISEOFULVIN; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LOPERAMIDE; MEVINOLIN; MORPHINE; NELFINAVIR; NIFEDIPINE; PHENOBARBITAL; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TERBINAFINE; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE;

ANTIFUNGAL ACTIVITY; BLEEDING; BLOOD TOXICITY; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; EDEMA; FLUSHING; HEADACHE; HEART DISEASE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; IATROGENIC DISEASE; LIVER TOXICITY; LONG QT SYNDROME; MYCOSIS; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; PHOTOSENSITIVITY DISORDER; PRIAPISM; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SOMNOLENCE; TINNITUS; TORSADE DES POINTES;

EID: 0041512977     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00037-8     Document Type: Review

References (112)

1. Gupta AK, Shear NH. The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venereol 1999;13:1-13.
2. Diflucan (fluconazole). Package insert information. New York: Roerig, Division of Pfizer; 1998.
3. Gris-PEG (griseofulvin). Package insert information. Farmingdale, NY: Peninol Pharmacal; 2001.
4. Sporanox (itraconazole). Package insert information. Titusville, NJ: Janssen Pharmaceutica; 2001.
5. Nizoral (ketoconazole). Package insert information. Titusville, NJ: Janssen Pharmaceuticals; 1998.
6. Lamisil oral (terbinafine). Package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2001.
7. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf 2000;22:33-52.
8. De Doncker P. Itraconazole and terbinafine in perspective: from petri dish to patient. J Eur Acad Dermatol Venereol 1999;12(suppl 1):S10-6.
9. Harrell TK, Necomb WW, Replogle WH, King DS, Noble SL. Onychomycosis: improved cure rates with itraconazole and terbinafine. J Am Board Fam Pract 2000;13:268-73.
10. Roos TC, Merk HF. Important drug interactions in dermatology. Drugs 2000;59:181-92.
11. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001;40:833-68.
12. Katz HI, Gupta AK. Oral antifungal drug interactions. Dermatol Clin 1997;15:535-44.
13. Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol 1999;41(2 pt 1): 237-49.
14. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80.
15. Shear N, Drake L, Gupta AK, Lambert J, Yaniv R. The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology 2000;201:196-203.
16. Brodell RT, Elewski B. Antifungal drug interactions: avoidance requires more than memorization. Postgrad Med 2000;107:41-3.
17. Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? [editorial; comment] Canadian Medical Association Journal 1999;161:1266-7.
18. Farup C, George MJ. Important safety information health profession communication from Janssen Pharmaceutica Products regarding a warning about occurrence of congestive heart failure and the administration Sporanox Capsules. 2001.
19. Persat F, Schwartzbrod PE, Troncy J, Timour Q, Maul A, Piens MA, et al. Abnormalities in liver enzymes during simultaneous therapy with itraconazole and amphotericin B in leukaemic patients. J Antimicrob Chemother 2000;45:928-9.
20. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001;2:51-64.
21. Grant EM. Optimizing the bioavailability of itraconazole. Conn Med 2000;64:415-7.
22. Willems L, van der GR, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001;26:159-69.
23. Chiou WL, Chung SM, Wu TC. Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharmacol Res 2000;17:903-5.
24. Mathis S. Role of CYP3A4 and P-glycoprotein in drug interactions involving the HMG-CoA reductase inhibitors. J Am Pharm Assoc 2001;41:5-6.
25. van Asperen J, van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998;37:429-35.
26. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001;21:778-96.
27. Pauli-Magnus C, Murdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, et al. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol 2001;363:337-43.
28. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000;22:137-40.
29. Mathis AS, Friedman GS. Coadministration of digoxin with itraconazole in renal transplant recipients. Am J Kidney Dis 2001;37:E18.
30. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician 1998;57:107-16.
31. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
32. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001;41:1149-79.
33. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
34. Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 2002;30:314-8.
35. Singer MI, Shapiro LE, Shear NH. Cytochrome P-450 3A: interactions with dermatologic therapies. J Am Acad Dermatol 1997;37:765-71.
36. Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 1999;65:465-72.
37. Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos 1999;27:770-5.
38. van der Kuy PH, Hooymans PM. Nortriptyline intoxication induced by terbinafine. BMJ 1998;316:441.
39. Schmutz JL, Barbaud A, Trechot P. [Surdosage en nortriptyline lors d'un traitement par terbinafine (ler cas rapporte).]. Ann Dermatol Venereol 1999;126:647.
40. O'Reardon JP, Hetznecker JM, Rynn MA, Baldassano CF, Szuba MP. Desipramine toxicity with terbinafine. Am J Psychiatry 2002;159:492.
41. Teitelbaum ML, Pearson VE. Imipramine toxicity and terbinafine. Am J Psychiatry 2001;158:2086.
42. Kaplan DL. Terbinafine and potential drug interactions. J Am Acad Dermatol 2000;43(5 pt 1):882-4.
43. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997; 133:1213-9.
44. Vickers AE. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 1999;27:1029-38.
45. Katz HI. Possible drug interactions in oral treatment of onychomycosis. J Am Podiatr Med Assoc 1997;87: 571-4.
46. Elewski B, Smith S. The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive. Cutis 2001;68(1 suppl):23-9.
47. Gupta R, Mittal A, Bhatnagar LK, Bansal NK. Oral hypoglycemics and azoles: an important drug interaction. J Assoc Physicians India 2001;49:676.
48. Verspeelt J, Marynissen G, Gupta AK, De Doncker P. Safety of itraconazole in diabetic patients. Dermatology 1999;198:382-4.
49. Wei X. FDA clinical pharmacology & biopharmaceutics review of Bristol Myers Squibb NDA21-198 submission. Available at: http://www.fda.gov/ohrms/ dockets/ac/00/backgrd/3622b2b. Clinical.pdf for approval of pravastatin switch to over the counter status, page 4-5, dated May 24, 2000. Accessed 2001.
50. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002; 46:160-5.
51. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38.
52. Caraco Y. Genetic determinants of drug responsiveness and drug interactions. Ther Drug Monit 1998;20: 517-24.
53. Aeschlimann JR, Tyler LS. Drug interactions associated with cytochrome P-450 enzymes. Journal of Pharmaceutical Care in Pain and Symptom Control 1996;4:35-54.
54. Greenblatt DJ. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999;19(suppl 1): 23S-35S.
55. Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther 1999;24:7-16.
56. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 1998;23:403-16.
57. Amphotec (amphotericin B). Package insert information. Menlo Park, CA: Sequus Pharmaceuticals; 2001.
58. Celebrex (celecoxib). Package insert information. Chicago: GD Searle and Company; 2000.
59. Celexa (citalopram). Package insert information. St Louis: Forest Pharmaceuticals; 2000.
60. Neoral (cyclosporine). Package insert information. East Hanover, NJ: Novartis Pharmaceuticals; 2001.
61. Tikosyn (dofetilide). Package insert information. New York: Pfizer Laboratories; 1999.
62. Versed (midazolam). Package insert information. Nutley, NJ: Roche Laboratories; 1998.
63. Orap (pimozide). Package insert information. Sellersville, PA: Gate Pharmaceuticals, Division of Teva Pharmaceuticals; 1999.
64. Tiao GM, Martin J, Weber FL, Cohen RM, Hanto DW. Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. Clin Transplant 1999; 13(1 pt 1):62-4.
65. Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC. Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. Antimicrob Agents Chemother 2000; 44:2170-2.
66. Viagra (sildenafil citrate). Package insert information. New York: Pfizer Labs, Division of Pfizer; 2000.
67. Zocor (simvastatin). Package insert information. West Point, PA: Merck & Co.; 2000.
68. Rapamune (sirolimus). Package insert information. Philadelphia: Wyeth-Ayerst Laboratories; 2001.
69. Prograf (tacrolimus). Package insert information. Deerfield, IL: Fujisawa Healthcare; 2001.
70. Konishi H, Morita K, Yamaji A. Effect of fluconazole on theophylline disposition in humans. Eur J Clin Pharmacol 1994;46:309-12.
71. Halcion (triazolam). Package insert information. Kalamazoo, MI: Pharmacia and Upjohn; 1999.
72. Coumadin (warfarin). Package insert information. Wilmington, DE: Dupont Pharmaceuticals; 2001.
73. Brockmeyer NH, Tillmann I, Mertins L, Barthel B, Goos M. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res 1997;29:377-83.
74. Trapnell CB, Klecker RW, Jamis-Dow C, Collins JM. Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob Agents Chemother 1998;42:1592-6.
75. Phillips K, Munster DJ, Allardyce RA, Bagshaw PF. Antibacterial action of the urease inhibitor acetohydroxamic acid on Helicobacter pylori. J Clin Pathol 1993;46:372-3.
76. Photofrin (porfimer). Package insert information. New York: Sanofi Pharmaceuticals; 1999.
77. Rasmussen BB, Jeppesen U, Gaist D, Brosen K. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Ther Drug Monit 1997;19: 56-62.
78. Xanax (alprazolam). Package insert information. Kalamazoo, MI: Pharmacia and Upjohn; 2000.
79. Amprenavir (agenerase). Package insert information. Research Triangle Park, NC: Glaxo Wellcome; 2001.
80. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400.
81. Lipitor (atorvastatin). Package insert information. Morris Plains, NJ: Parke-Davis, Division of Warner-Lambert Company; 2000.
82. Targretin (bexarotene). Package insert information. San Diego, CA: Ligand Pharmaceutical; 1999.
83. Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996;16:2083-8.
84. Tegretol (carbamazepine). Package insert information. East Hanover, NJ: Novartis Pharmaceutical; 2001.
85. Pletal (cilostazol). Package insert information. Tokushima, Japan: Otsuka Pharmaceuticals; 1999.
86. Ito S, Koren G. Comment: possible mechanism of digoxin-itraconazole interaction [letter]. Ann Pharmacother 1997;31:1091-2.
87. Kanda Y, Kami M, Matsuyama T, Mitani K, Chiba S, Yazaki Y, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998;16:33-7.
88. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. J Am Acad Dermatol 1995;33:134-5.
89. Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 1999;21:304-9.
90. Yasui N, Kondo T, Otani K, Furukori H, Mihara K, Suzuki A, et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol 1999;19: 149-54.
91. Crixivan (indinavir). Package insert information. West Point, PA: Merck and Company; 2001.
92. Wynn RL, Meiller TF, Crossley HL. Drug interactions: important new developments for dentistry. Tex Dent J 1999;116:54-60.
93. Crixivan (indinavir). Package insert information. West Point, PA: Merck and Company; 1999.
94. Prevacid package insert. Deerfield, IL: Tap Pharmaceuticals; 2000.
95. Depo-Medrol (methylprednisolone). Package insert information. Kalamazoo, MI: Pharmacia and Upjohn Company; 1999.
96. Viramune (nevirapine). Package insert information. Columbus, OH: Roxane Laboratories; 2000.
97. Oakes ML. Personal communication (letter from Maureen I. Oakes, Pharm. D., medical information specialist, Roxane Laboratories, Inc., Ridgefield, CT) on September 15, 1997.
98. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998;54:159-61.
99. Norvir (ritonavir). Package insert information. North Chicago, IL: Abbott Laboratories; 2000.
100. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147-69.
101. Fortovase (saquinavir). Package insert information. Nutley, NJ: Roche Laboratories; 2000.
102. Viagra (sildenafil citrate). Package insert information. New York: Pfizer Labs, Division of Pfizer; 1999.
103. Carafate (sucralfate). Package insert. Kansas City, MO: Aventis Pharmaceuticals; 2000.
104. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998;18:1304-7.
105. Matsunaga T, Kishi N, Higuchi S, Watanabe K, Ohshima T, Yamamoto I. CYP3A4 is a major isoform responsible for oxidation of 7-hydroxy-Delta(8)-tetrahydrocannabinol to 7-oxo-delta(8)-tetrahydrocannabinol in human liver microsomes. Drug Metab Dispos 2000;28:1291-6.
106. Long CC, Hill SA, Thomas RC, Johnston A, Smith SG, Kendall F, et al. Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. J Invest Dermatol 1994;102:740-3.
107. Jensen P, Lehne G, Fauchald P, Simonsen S. Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection. Acta Derm Venereol 1996;76:280-1.
108. Trepanier EF, Nafziger AN, Amsden GW. Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 1998;42:695-7.
109. Warwick JA, Corrall RJ. Serious interaction between warfarin and oral terbinafine. BMJ 1998;316:440.
110. Gupta AK, Ross GS. Interaction between terbinafine and warfarin. Dermatology 1998;196:266-7.
111. van der Kuy PH, van den Heuvel H, van den Heuvel HA, Kempen R, Kempen RW, Vanmolkot L, et al. Pharmacokinetic interaction between nortriptyline and terbinafine. Ann Pharmacother 2002;36(11): 1712-4.
112. Gantmacher J, Mills-Bomford J, Williams T. Interaction between warfarin and oral terbinafine: manufacturer does not agree that interaction was with terbinafine [letter]. BMJ 1998;317:205.